Compare HST & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HST | JAZZ |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 10.8B |
| IPO Year | N/A | 2007 |
| Metric | HST | JAZZ |
|---|---|---|
| Price | $18.36 | $167.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $18.65 | ★ $199.20 |
| AVG Volume (30 Days) | ★ 7.1M | 1.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 3.27 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $5,950,000,000.00 | $4,157,832,999.00 |
| Revenue This Year | $6.31 | $6.00 |
| Revenue Next Year | $1.80 | $6.84 |
| P/E Ratio | $17.35 | ★ N/A |
| Revenue Growth | ★ 6.44 | 4.14 |
| 52 Week Low | $12.22 | $95.49 |
| 52 Week High | $19.03 | $182.99 |
| Indicator | HST | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | 57.75 |
| Support Level | $17.04 | $161.00 |
| Resistance Level | $17.69 | $168.69 |
| Average True Range (ATR) | 0.37 | 4.96 |
| MACD | 0.06 | -1.99 |
| Stochastic Oscillator | 89.42 | 30.32 |
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.